BA
AIMT

BlackRock Advisors’s Aimmune Therapeutics AIMT Stock Holding History

BlackRock Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$265K Sell
12,955
-315
-2% -$6.44K ﹤0.01% 2565
2016
Q3 		$199K Buy
13,270
+4,471
+51% +$60.4K ﹤0.01% 2698
2016
Q2 		$95K Buy
8,799
+4,722
+116% +$64.2K ﹤0.01% 2993
2016
Q1 		$55K Buy
4,077
+393
+11% +$6.13K ﹤0.01% 3136
2015
Q4 		$68K Sell
3,684
-1,608
-30% -$29.7K ﹤0.01% 3090
2015
Q3 		$134K Buy
+5,292
New +$124K ﹤0.01% 2955

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BlackRock Advisors's AIMT Position: Q4 2016 in Review

BlackRock Advisors reduced its Aimmune Therapeutics (AIMT) stake by 2.4% in Q4 2016, selling an estimated $6.44K and leaving 12,955 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #2565.

BlackRock Advisors first reported a position in AIMT in Q3 2015 and has held it in 6 quarters since. 92 funds tracked by Wall St. Rank hold AIMT as of Q4 2016.

  • BlackRock Advisors held 12,955 shares of Aimmune Therapeutics worth $265K as of Q4 2016.
  • BlackRock Advisors sold 315 Aimmune Therapeutics shares in Q4 2016, an estimated $6.44K.
  • Aimmune Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2565 holding.
  • BlackRock Advisors first reported a position in Aimmune Therapeutics in Q3 2015 and has held it in 6 quarters since.
  • 92 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.